ESR1 and breast cancer: For instance, recent studies have shown that blockade of mTORC1 signalling in combination with AI therapy causes a marked increase in PFS in patients with metastatic ER+ BC (BOLERO-2) [7]; however, relapse remains a significant clinical issue.